CN1173718C - Medicine for curing lupus erythematosus etc. immune diseases induced diseases - Google Patents
Medicine for curing lupus erythematosus etc. immune diseases induced diseases Download PDFInfo
- Publication number
- CN1173718C CN1173718C CNB011044756A CN01104475A CN1173718C CN 1173718 C CN1173718 C CN 1173718C CN B011044756 A CNB011044756 A CN B011044756A CN 01104475 A CN01104475 A CN 01104475A CN 1173718 C CN1173718 C CN 1173718C
- Authority
- CN
- China
- Prior art keywords
- medicine
- radix
- lupus erythematosus
- agkistrodon
- root
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000003814 drug Substances 0.000 title claims abstract description 25
- 206010025135 lupus erythematosus Diseases 0.000 title claims abstract description 11
- 208000026278 immune system disease Diseases 0.000 title claims abstract description 9
- 229940079593 drug Drugs 0.000 title description 6
- 201000010099 disease Diseases 0.000 title description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title description 4
- 208000006820 Arthralgia Diseases 0.000 claims abstract description 6
- 241000271039 Agkistrodon Species 0.000 claims description 11
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims description 7
- 241000903946 Clematidis Species 0.000 claims description 6
- 241000283956 Manis Species 0.000 claims description 6
- 210000003038 endothelium Anatomy 0.000 claims description 6
- 244000025254 Cannabis sativa Species 0.000 claims description 5
- 208000011580 syndromic disease Diseases 0.000 claims description 5
- 239000002552 dosage form Substances 0.000 claims description 2
- 208000002193 Pain Diseases 0.000 abstract description 5
- 210000003205 muscle Anatomy 0.000 abstract description 4
- 208000012322 Raynaud phenomenon Diseases 0.000 abstract description 2
- 230000036737 immune function Effects 0.000 abstract description 2
- 241000271897 Viperidae Species 0.000 abstract 2
- 241000427159 Achyranthes Species 0.000 abstract 1
- 241000218158 Clematis Species 0.000 abstract 1
- 244000150195 Cyperus longus Species 0.000 abstract 1
- 241000208368 Euonymus alatus Species 0.000 abstract 1
- 244000192024 Euphorbia helioscopia Species 0.000 abstract 1
- 235000012043 Euphorbia helioscopia Nutrition 0.000 abstract 1
- 241000501743 Gentiana macrophylla Species 0.000 abstract 1
- 241000283966 Pholidota <mammal> Species 0.000 abstract 1
- 208000003782 Raynaud disease Diseases 0.000 abstract 1
- 241000405414 Rehmannia Species 0.000 abstract 1
- 241001482963 Thamnophis Species 0.000 abstract 1
- 230000007547 defect Effects 0.000 abstract 1
- 208000037920 primary disease Diseases 0.000 description 4
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 241000411851 herbal medicine Species 0.000 description 3
- 206010025482 malaise Diseases 0.000 description 3
- 231100000862 numbness Toxicity 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 208000030507 AIDS Diseases 0.000 description 2
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 2
- 229960003444 immunosuppressant agent Drugs 0.000 description 2
- 230000001861 immunosuppressant effect Effects 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 102000007501 Thymosin Human genes 0.000 description 1
- 108010046075 Thymosin Proteins 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 230000000781 anti-lymphocytic effect Effects 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000006757 chemical reactions by type Methods 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000005202 decontamination Methods 0.000 description 1
- 230000003588 decontaminative effect Effects 0.000 description 1
- 238000012631 diagnostic technique Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229960001614 levamisole Drugs 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 208000037890 multiple organ injury Diseases 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- LCJVIYPJPCBWKS-NXPQJCNCSA-N thymosin Chemical compound SC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CO)C(=O)N[C@H](CO)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O LCJVIYPJPCBWKS-NXPQJCNCSA-N 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to medicine for treating immunological diseases caused by the hypofunction, the disturbance, the defect, etc. of the immunological function, which is prepared from pangolin, long-noded pit viper, hundred-pace viper, cortex moutan, rehmannia root, ivory flake, parched nutgrass galingale rhizome, clematis root, large-leaf gentian root, achyranthes root, garter snake, winged euonymus twig, euphorbia helioscopia and other traditional Chinese medicine according to a certain technology. The medicine can be used for treating arthralgia, whole body muscle sore pain and blocked extremities (the Raynaud's disease) caused by the immunological diseases, such as lupus erythematosus, etc.
Description
The present invention relates to a kind of arthralgia-syndrome resulted medicine of lupus erythematosus immune disease for the treatment of, be specifically with the Chinese herbal medicine be raw material according to the Chinese patent medicine that special process is prepared from, belong to the field of Chinese medicines.
Systemic lupus erythematosus (sle) is that world's medical matters circle are referred to as one of four big difficult disease of wrecking the human life, and domestic and international interrelated data report, the sickness rate that every year should disease to be rapidly increasing progressively by a relatively large margin, to the mankind's threat not second to cancer and acquired immune deficiency syndrome (AIDS).In areas such as the Luo Qisite of the U.S., California, the sickness rate in its members of the same clan exceeds hundreds of times of general crowd up to 0.4-5%.Black people's sickness rate is three times in general crowd, and in the Black women of 15-45, per 245 people have a people to suffer from lupus erythematosus, is more common in the 15-25 young women in year especially.Before not using the 17-hydroxy-11-dehydrocorticosterone treatment, the primary disease mortality rate is very high, 80% patient dies from primary disease in 2 years, in recent years because the progress of diagnostic techniques and utilization 17-hydroxy-11-dehydrocorticosterone, the utilization of immunosuppressant, levamisole, antiviral drugs, antilymphocyte globulin thymosin and Chinese herbal medicine, the primary disease mortality rate progressively descends, and best survival rate has reached 80-85% in present 10 years.Though change is arranged, but, still have the part patient to die from organa parenchymatosums such as the heart, kidney, the brain infringement and the complication of primary disease because of various factors, hormone and the immunosuppressant of using both at home and abroad brought potential infection and transition to use this type of medicine to suppress the normal immunologic function of body to patient at present, destroyed organism balance, the patient is caused a disease because of lupus erythematosus, is exactly to cause death because of side effects of pharmaceutical drugs.Particularly, systemic lupus erythematosus (sle) is the autoimmune disease that causes multiple organ injury, often causes the performance of arthromyodynias such as arthralgia, whole body muscle Chu pain and the resistance of extremity numbness be obstructed clinically, brings very big misery to patient.At present still there is not to alleviate and to treat effective medicine of the caused arthromyodynia of above-mentioned lupus erythematosus clinically.
The object of the invention provides the arthralgia-syndrome resulted medicine of a kind of effective treatment lupus erythematosus immune disease.
Medicine of the present invention is that the Chinese herbal medicine by the following weight proportioning forms according to certain prepared:
Squama Manis 20-35
Agkistrodon 3-5
Agkistrodon 2.5-6
Cortex Moutan 15-20
Radix Rehmanniae 30-40
Dens Elephatis 2-9
Fry Rhizoma Cyperi 15-25
Radix Clematidis 8-15
Radix Gentianae Macrophyllae 15-20
Radix Cyathulae 15-25
Zaocys 10-15
Ramulus Euonymi 15-30
Herba Euphorbiae Helioscopiae 8-15
Ramulus Mori 15-25
Grass Herba Dendrobii 25-35
Endothelium Corneum Gigeriae Galli 10-15
Radix Paeoniae Alba 15-20
Rhizoma Polygonati Odorati 10-15
Medicine of the present invention preferably is prepared from by the Chinese medicine of following weight parts:
Squama Manis 26
Agkistrodon 4
Agkistrodon 4
Cortex Moutan 18
The Radix Rehmanniae 35
Dens Elephatis 5
Fry Rhizoma Cyperi 20
Radix Clematidis 10
Radix Gentianae Macrophyllae 18
Radix Cyathulae 20
Zaocys 12
Ramulus Euonymi 20
Herba Euphorbiae Helioscopiae 10
Ramulus Mori 20
Grass Herba Dendrobii 30
Endothelium Corneum Gigeriae Galli 13
Radix Paeoniae Alba 18
Rhizoma Polygonati Odorati 13
Medicine of the present invention can be prepared into pharmaceutical dosage form commonly used clinically according to common process, preferred capsule.
Medicine of the present invention is according to Traditional Chinese medical theory, and the prescription compatibility is applicable to because of the caused whole body of lupus erythematosus and other immunological disease numbness resistance pain, nourishing YIN easing the affected liver such as the Radix Rehmanniae, careless Herba Dendrobii, Radix Paeoniae Alba in the side, nourishing muscle and tendon arteries and veins; Squama Manis, stir-fry Rhizoma Cyperi, the resistance of Radix Cyathulae vital energy regualting and blood circulation-promoting repercussive; Radix Clematidis, Radix Gentianae Macrophyllae, Ramulus Mori, Zaocys, Agkistrodon wind dispelling collateral dredging are searched wind to the marrow, but and the removing dampness blood stasis dispelling, add Ramulus Euonymi and more increase its merit; Herba Euphorbiae Helioscopiae detoxifcation row wets and exercises pathogenic factor down from the urine dry measure used in former times; Herba Dendrobii, Rhizoma Polygonati Odorati, Radix Paeoniae Alba share, but nourishing stomach-YIN again, to turn round and look at wet soil; Endothelium Corneum Gigeriae Galli helps spleen fortune chemical medicine power, plays harmonizing the liver and spleen, dehumidifying blood stasis dispelling, the active merit of dispelling wind altogether.This drug effect both can promote the lymphocytic conversion of T behind human body, improve spleen plaque forming cells haematolysis ability, to increase antibody, and can suppress the III allergic reaction type, can be used to treat the caused joint of lupus erythematosus immune disease pain, whole body muscle Chu pain and extremity numbness resistance obstructed (raynaud's sign), have good therapeutic effect.Through experiment confirm, this product does not have any toxicity.
Embodiment:
Choose raw material according to following composition
Squama Manis 26
Agkistrodon 4
Agkistrodon 4
Cortex Moutan 18
The Radix Rehmanniae 35
Dens Elephatis 5
Fry Rhizoma Cyperi 20
Radix Clematidis 10
Radix Gentianae Macrophyllae 18
Radix Cyathulae 20
Zaocys 12
Ramulus Euonymi 20
Herba Euphorbiae Helioscopiae 10
Ramulus Mori 20
Grass Herba Dendrobii 30
Endothelium Corneum Gigeriae Galli 13
Radix Paeoniae Alba 18
Rhizoma Polygonati Odorati 13
With said medicine, pick up decontamination, clean, add water and do not have powder, decoct twice, each 1 hour, merge decoction liquor twice, concentrate fluid extract, add appropriate amount of starch, pelletize, tabletting promptly makes tablet.
Claims (3)
1, a kind of arthralgia-syndrome resulted medicine of lupus erythematosus immune disease for the treatment of is characterized in that this medicine is that Chinese medicine by following weight parts is prepared from:
Squama Manis 20-35
Agkistrodon 3-5
Agkistrodon 2.5-6
Cortex Moutan 15-20
Radix Rehmanniae 30-40
Dens Elephatis 2-9
Fry Rhizoma Cyperi 15-25
Radix Clematidis 8-15
Radix Gentianae Macrophyllae 15-20
Radix Cyathulae 15-25
Zaocys 10-15
Ramulus Euonymi 15-30
Herba Euphorbiae Helioscopiae 8-15
Ramulus Mori 15-25
Grass Herba Dendrobii 25-35
Endothelium Corneum Gigeriae Galli 10-15
Radix Paeoniae Alba 15-20
Rhizoma Polygonati Odorati 10-15.
2, medicine according to claim 1 is characterized in that this medicine is that Chinese medicine by following weight parts is prepared from:
Squama Manis 26
Agkistrodon 4
Agkistrodon 4
Cortex Moutan 18
The Radix Rehmanniae 35
Dens Elephatis 5
Fry Rhizoma Cyperi 20
Radix Clematidis 10
Radix Gentianae Macrophyllae 18
Radix Cyathulae 20
Zaocys 12
Ramulus Euonymi 20
Herba Euphorbiae Helioscopiae 10
Ramulus Mori 20
Grass Herba Dendrobii 30
Endothelium Corneum Gigeriae Galli 13
Radix Paeoniae Alba 18
Rhizoma Polygonati Odorati 13.
3, medicine according to claim 1, the dosage form that it is characterized in that this medicine is a tablet.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB011044756A CN1173718C (en) | 2001-02-27 | 2001-02-27 | Medicine for curing lupus erythematosus etc. immune diseases induced diseases |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB011044756A CN1173718C (en) | 2001-02-27 | 2001-02-27 | Medicine for curing lupus erythematosus etc. immune diseases induced diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1311025A CN1311025A (en) | 2001-09-05 |
| CN1173718C true CN1173718C (en) | 2004-11-03 |
Family
ID=4653931
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB011044756A Expired - Lifetime CN1173718C (en) | 2001-02-27 | 2001-02-27 | Medicine for curing lupus erythematosus etc. immune diseases induced diseases |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1173718C (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100337676C (en) * | 2005-07-05 | 2007-09-19 | 孙振华 | Erythromelalgia treating medicine |
| CN101185736B (en) * | 2007-12-11 | 2011-11-16 | 叶福兰 | Orally-administered traditional Chinese medicine for treating acute lupus erythematosus |
| CN101502629B (en) * | 2009-03-19 | 2012-02-22 | 大连大学 | A traditional Chinese medicine compound preparation for treating systemic lupus erythematosus |
-
2001
- 2001-02-27 CN CNB011044756A patent/CN1173718C/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CN1311025A (en) | 2001-09-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1476849A (en) | Medicine composition for promoting blood circulation and removing stasis | |
| CN1054773C (en) | Chinese patent drug "Bizhengning" for treatment of arthralgia-syndrome | |
| CN1173718C (en) | Medicine for curing lupus erythematosus etc. immune diseases induced diseases | |
| CN1698738A (en) | Chinese medicine for treating cancer | |
| CN1051471C (en) | A kind of pharmaceutical composition for treating osteoporosis | |
| CN101199749A (en) | Chinese medicine for treating AIDS | |
| CN1840170A (en) | Chinese proprietary medicine for treating cerebral thrombosis | |
| CN1107711A (en) | Hypoglycemic compound capsule | |
| CN1292766C (en) | Chinese medicinal preparation for treating viral myocarditis and its making method | |
| CN1301544A (en) | Medicinal composition for curing arthritis and osteoarthropathy and its preparing method | |
| CN1116890C (en) | Medicine for treating hepatitis B | |
| CN1086586C (en) | Medicine for treating cardiac and cerebral vascular diseases and its preparation | |
| CN100336547C (en) | Medicine for treating hypertension | |
| CN1682809A (en) | Strong itching relieving pill for treating intractable pruritus caused by skin diseases | |
| CN1126558C (en) | Medicine for treating kidney damage caused by immunological disease lupus erythematosus | |
| CN1150015C (en) | Medicine for treating leucocytopenia caused by lupus erythematosus | |
| CN1137713C (en) | Chinese medicine oral preparation for curing apoplectic disease-Suyusan and its preparation method | |
| CN1682811A (en) | Ridge and bone strengthening pill for treating ankylosing spondylitis | |
| CN1150016C (en) | Medicine for treating fever caused by lupus erythematosus and other immunological disease | |
| CN1059574C (en) | Chinese medicine preparation | |
| CN1150014C (en) | Lupus erythematosus treating medicine | |
| CN1212150C (en) | Medicine for treating virus hepatitis and its preparation method | |
| CN1049596C (en) | Medicine composite for curing arthritis | |
| CN1207944A (en) | Rheumatism capsule | |
| CN1194734C (en) | Pill for treating hepatitis B |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CX01 | Expiry of patent term | ||
| CX01 | Expiry of patent term |
Granted publication date: 20041103 |